文献速递眼底病与葡萄膜炎

新生血管性年龄相关性黄斑变性继发黄斑纤维化:从临床到生物学

Macular fibrosis secondary to neovascular age-related macular degeneration: from clinic to biology.
PubMed 文献 · Prog Retin Eye Res · 2026-06-07

本文综述新生血管性年龄相关性黄斑变性(nAMD)继发黄斑视网膜下纤维化的临床特征、病理机制与治疗前景。尽管广泛使用抗VEGF治疗,20%至67%的nAMD患者在2至7年内发生该病变,是抗VEGF抵抗和不可逆视力丧失的主要原因之一。视网膜下纤维化是动态血管化病变,伴持续活跃炎症,称为「热纤维化」,临床高分辨率成像和尸检病理揭示其特征,临床前模型提示双重靶向药物和抗纤维化药物眼部递送等新策略。

要点

  • nAMD患者中20%至67%在2至7年内发生黄斑视网膜下纤维化。
  • 纤维化是抗VEGF抵抗和不可逆视力丧失的主要原因之一。
  • 视网膜下纤维化为动态血管化「热纤维化」病变,伴持续活跃炎症。

核心结论

  • 黄斑视网膜下纤维化是nAMD的终末期并发症,也是抗VEGF抵抗和不可逆视力丧失的主要原因之一。
  • 视网膜下纤维化是动态血管化病变,伴持续活跃炎症,称为「热纤维化」。
  • 双重靶向药物和抗纤维化药物眼部递送是值得探索的治疗方向。

研究设计与样本

  • 本文为综述,总结nAMD黄斑纤维化的临床特征、高级临床高分辨率成像和尸检组织病理学见解,并探讨临床前模型揭示的发病机制和新治疗靶点。

主要发现

  • 尽管广泛使用抗VEGF治疗,20%至67%的nAMD患者在2至7年内发生黄斑视网膜下纤维化。
  • 视网膜下纤维化是动态血管化病变,伴持续活跃炎症,称为「热纤维化」。
  • 驱动新生血管转化为纤维血管膜的分子机制仍不明确。

关键数值与推荐

  • nAMD患者中20%至67%在2至7年内发生黄斑视网膜下纤维化。

临床怎么用

  • 关注nAMD患者黄斑纤维化的发生风险,并将其作为抗VEGF抵抗和视力丧失的重要原因。
  • 关注双重靶向药物(如抑制VEGF和Ang-2或补体通路)及抗纤维化药物眼部递送等新治疗策略。

局限性

  • 驱动新生血管转化为纤维血管膜的分子机制仍不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Macular subretinal fibrosis represents the end-stage complication of neovascular age-related macular degeneration (nAMD). Despite the widespread use of anti-VEGF therapy, between 20 and 67% of nAMD patients develop this sight-threatening condition within 2 to 7 years, making fibrosis one of the main reasons responsible for anti-VEGF resistance and irreversible visual loss. Unlike the quiescent scar of a healed skin wound, subretinal fibrosis is a dynamic, vascularised lesion characterised by persistent and active inflammation, a process aptly termed "hot fibrosis". The molecular mechanisms that drive the conversion of neovascularisation into fibrovascular membrane remain poorly defined. This review summarises the clinical features of macular fibrosis in nAMD. It will then detail the pathological insights gained from advanced clinical high-resolution imaging and post-mortem histopathological investigations. We will also explore how advances in our understanding of the pathogenesis of macular fibrosis, as revealed by preclinical models, are uncovering novel therapeutic targets. Promising approaches include dual-targeting agents (e.g., inhibiting VEGF and Ang-2 or complement pathways), as well as repurposing FDA-approved anti-fibrotics, such as pirfenidone or nintedanib, for ocular delivery. The repurposing of drugs with established safety profiles, reformulated for local intraocular use, offers a particularly resource-efficient pathway.

来源:Prog Retin Eye Res,查看原文。版权归原作者所有。

引用

  1. Xu H, Pu J, Yi C, et al. Macular fibrosis secondary to neovascular age-related macular degeneration: from clinic to biology. Prog Retin Eye Res. 2026. PMID: 42259444. doi:10.1016/j.preteyeres.2026.101488

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。